---
title: "Regeneron rises after strong Q2 beat powered by high-dose Eylea"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294356445.md"
description: "Regeneron Pharmaceuticals (REGN) shares rose in premarket trading after reporting Q2 2026 results that beat street estimates. The company posted $4.2 billion in revenue, driven primarily by strong sales of its new high-dose Eylea eye therapy."
datetime: "2026-07-30T11:32:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294356445.md)
  - [en](https://longbridge.com/en/news/294356445.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294356445.md)
generator: "portal-rs"
---

# Regeneron rises after strong Q2 beat powered by high-dose Eylea

Shares of Regeneron Pharmaceuticals (REGN) gained in the premarket on Thursday after the U.S. drugmaker reported Q2 2026 results exceeding the Street estimates comfortably, mainly due to higher sales from the new high-dose version of its eye therapy, Eylea. The Tarrytown, New York-based firm reported $4.2B in revenue for the quarter, indicating ~17...

### Related Stocks

- [REGN.US](https://longbridge.com/en/quote/REGN.US.md)

## Related News & Research

- [18:14 ETRegeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit](https://longbridge.com/en/news/297093753.md)
- [Why Veeva Systems (VEEV) Is Up 11.6% After Strong Q2, Higher Guidance, and New AI CRM Wins](https://longbridge.com/en/news/297419205.md)
- [Does First-in-Class FOP Drug Approval Transform the Bull Case For Regeneron Pharmaceuticals (REGN)?](https://longbridge.com/en/news/296702017.md)
- [Regeneron podcast turns science into immersive experience](https://longbridge.com/en/news/296758441.md)
- [12:50 ETREGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt](https://longbridge.com/en/news/295826897.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**